{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:19:37Z","timestamp":1785406777821,"version":"3.56.0"},"reference-count":48,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016328","name":"Fondation du cancer du sein du Qu\u00e9bec","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016328","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/00dfyw498","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Fonds de recherche du Qu\u00e9bec-Sant\u00e9","award":["#313085"],"award-info":[{"award-number":["#313085"]}]},{"name":"Fonds de recherche-Sant\u00e9","award":["FRQ-S"],"award-info":[{"award-number":["FRQ-S"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>This pilot study (NCT05743686) evaluated the feasibility of a web-based application enabling patients with breast cancer (BC) receiving oral therapy to self-report and manage treatment-related adverse effects (AEs). Patients were enrolled between January and August 2023. Historical controls were used for comparison. Participants used the web-app to self-report AEs daily for 13 weeks, completed the PRO-CTCAE weekly, and completed a questionnaire assessing psychosocial precursor factors associated with treatment adherence. Some patients and healthcare professionals participated in semi-structured interviews. The study included 28 participants and 185 historical controls. Compared with controls, participants had fewer interactions with hospital pharmacists (0 [0\u20131] vs. 0 [0\u20137], p = 0.04), with no significant differences in the number of visits, hospitalizations, or modifications to treatment. Concordance between AEs reported via the web-app and PRO-CTCAE was 66.2%. No statistically significant changes were observed in psychosocial precursor factors of treatment adherence following the intervention (all p &gt; 0.05). The qualitative data underscored the generally positive reception of the web-based application among both patients and healthcare professionals. In conclusion, in this small mixed-methods pilot study, monitoring oral cancer therapy-related adverse effects using the web-app was feasible and acceptable, and was associated with a lower frequency of telephone contacts with hospital pharmacists compared with historical usual care. These preliminary findings are exploratory and warrant confirmation in larger, prospectively designed studies.<\/jats:p>","DOI":"10.3390\/curroncol33050272","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T10:39:47Z","timestamp":1778150387000},"page":"272","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and Evaluation of a Web-Based App for Adverse Effect Management in Breast Cancer Patients Treated with Oral Targeted Therapy or Chemotherapy: Findings from a Pilot Study"],"prefix":"10.3390","volume":"33","author":[{"given":"Julie","family":"Lemieux","sequence":"first","affiliation":[{"name":"Centre des Maladies du Sein, CHU de Qu\u00e9bec\u2014Universit\u00e9 Laval, Quebec City, QC G1S 4L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"C\u00f4t\u00e9","sequence":"additional","affiliation":[{"name":"Centre des Maladies du Sein, CHU de Qu\u00e9bec\u2014Universit\u00e9 Laval, Quebec City, QC G1S 4L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Lemay","sequence":"additional","affiliation":[{"name":"Centre des Maladies du Sein, CHU de Qu\u00e9bec\u2014Universit\u00e9 Laval, Quebec City, QC G1S 4L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Lauzier","sequence":"additional","affiliation":[{"name":"Centre de Recherche du CHU de Qu\u00e9bec\u2014Universit\u00e9 Laval, Quebec City, QC G1V 4G2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4163-7353","authenticated-orcid":false,"given":"Philippe","family":"Despr\u00e9s","sequence":"additional","affiliation":[{"name":"Centre de Recherche du CHU de Qu\u00e9bec\u2014Universit\u00e9 Laval, Quebec City, QC G1V 4G2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Desbiens","sequence":"additional","affiliation":[{"name":"Centre des Maladies du Sein, CHU de Qu\u00e9bec\u2014Universit\u00e9 Laval, Quebec City, QC G1S 4L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Doyle","sequence":"additional","affiliation":[{"name":"Centre des Maladies du Sein, CHU de Qu\u00e9bec\u2014Universit\u00e9 Laval, Quebec City, QC G1S 4L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Poirier","sequence":"additional","affiliation":[{"name":"Centre des Maladies du Sein, CHU de Qu\u00e9bec\u2014Universit\u00e9 Laval, Quebec City, QC G1S 4L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amel","family":"Baghdadli","sequence":"additional","affiliation":[{"name":"Centre de Recherche du CHU de Qu\u00e9bec\u2014Universit\u00e9 Laval, Quebec City, QC G1V 4G2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Di Schiavi Trotta","sequence":"additional","affiliation":[{"name":"Centre de Recherche du CHU de Qu\u00e9bec\u2014Universit\u00e9 Laval, Quebec City, QC G1V 4G2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7832-0413","authenticated-orcid":false,"given":"Hermann","family":"Nabi","sequence":"additional","affiliation":[{"name":"Centre de Recherche du CHU de Qu\u00e9bec\u2014Universit\u00e9 Laval, Quebec City, QC G1V 4G2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","unstructured":"Canadian Cancer Statistics Advisory Committee, Canadian Cancer Society, Statistics Canada, and Public Health Agency of Canada (2025). Canadian Cancer Statistics 2025."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s12282-020-01054-7","article-title":"First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A systematic review and meta-analysis","volume":"27","author":"Shimoi","year":"2020","journal-title":"Breast Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s10549-013-2814-5","article-title":"Everolimus plus exemestane as first-line therapy in HR+, HER2- advanced breast cancer in BOLERO-2","volume":"143","author":"Beck","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-Mutated, Hormone Receptor\u2013Positive Advanced Breast Cancer","volume":"380","author":"Ciruelos","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in Hormone Receptor\u2013Positive Advanced Breast Cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): Results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus Endocrine Therapy in Early Breast Cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1634\/theoncologist.2016-0185","article-title":"Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+\/HER2- Advanced Breast Cancer","volume":"22","author":"Pritchard","year":"2017","journal-title":"Oncologist"},{"key":"ref_12","first-page":"35","article-title":"Adherence and health care costs","volume":"7","author":"Iuga","year":"2014","journal-title":"Risk Manag. Healthc. Policy"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/annonc\/mdt433","article-title":"Factors influencing adherence to cancer treatment in older adults with cancer: A systematic review","volume":"25","author":"Puts","year":"2014","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"ref_15","first-page":"1012","article-title":"Cost-Effectiveness of Web-Based Patient-Reported Outcome Surveillance in Patients with Lung Cancer","volume":"14","author":"Basch","year":"2019","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40264-016-0494-x","article-title":"Factors Influencing the Use of a Mobile App for Reporting Adverse Drug Reactions and Receiving Safety Information: A Qualitative Study","volume":"40","author":"Wong","year":"2017","journal-title":"Drug Saf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e13245","DOI":"10.2196\/13245","article-title":"Evidence on the Use of Mobile Apps During the Treatment of Breast Cancer: Systematic Review","volume":"7","author":"Cruz","year":"2019","journal-title":"JMIR mHealth uHealth"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: Building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J. Biomed. Inform."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1007\/s11764-024-01599-y","article-title":"Pilot randomized controlled trial of a program to enhance experience and adherence with adjuvant endocrine therapy among women with non-metastatic breast cancer: 12-month quantitative results","volume":"19","author":"Assan","year":"2024","journal-title":"J. Cancer Surviv."},{"key":"ref_21","unstructured":"Miles, M.B., Huberman, A.M., Rispal, M.H., and Bonniol, J.J. (2003). Analyse des Donn\u00e9es Qualitatives, De Boeck Sup\u00e9rieur."},{"key":"ref_22","unstructured":"Patton, M.Q. (2014). Qualitative Research & Evaluation Methods: Integrating Theory and Practice, SAGE Publications."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual. Res. Psychol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s11764-023-01513-y","article-title":"Interventions to improve oral endocrine therapy adherence in breast cancer patients","volume":"19","author":"Ganna","year":"2025","journal-title":"J. Cancer Surviv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"108145","DOI":"10.1016\/j.cct.2025.108145","article-title":"Improving CDK4\/6 inhibitors adherence in breast cancer using the Connected Customized Treatment Platform (CONCURxP) mobile health intervention: Study protocol for ECOG-ACRIN EAQ221CD","volume":"160","author":"Sadigh","year":"2025","journal-title":"Contemp. Clin. Trials"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e64208","DOI":"10.2196\/64208","article-title":"The Efficacy of Digital Interventions on Adherence to Oral Systemic Anticancer Therapy Among Patients with Cancer: Systematic Review and Meta-Analysis","volume":"11","author":"Liao","year":"2025","journal-title":"JMIR Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/pon.6203","article-title":"Interventions to increase adherence to oral therapies in breast cancer patients: A systematic review based on the behavior change technique taxonomy","volume":"32","author":"Pezzolato","year":"2023","journal-title":"Psycho-Oncology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.clbc.2024.12.011","article-title":"Oral Anticancer Therapies: Addressing Nonadherence in Patients with Breast Cancer","volume":"25","author":"Cazzaniga","year":"2025","journal-title":"Clin. Breast Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","article-title":"Recent progress of CDK4\/6 inhibitors\u2019 current practice in breast cancer","volume":"31","author":"Wang","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"ref_30","first-page":"231","article-title":"Adherence to targeted oral anticancer medications","volume":"15","author":"Geynisman","year":"2013","journal-title":"Discov. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1158\/1078-0432.CCR-17-2555","article-title":"Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site Inspections","volume":"24","author":"Kim","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1007\/s11136-023-03374-5","article-title":"Reliability and validity of PRO-CTCAE\u00ae daily reporting with a 24-hour recall period","volume":"32","author":"Lee","year":"2023","journal-title":"Qual. Life Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrclinonc.2015.222","article-title":"Patient-reported outcomes in the evaluation of toxicity of anticancer treatments","volume":"13","author":"Basch","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMp1114649","article-title":"Toward Patient-Centered Drug Development in Oncology","volume":"369","author":"Basch","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.2018.18085","article-title":"Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer","volume":"321","author":"Denis","year":"2019","journal-title":"JAMA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1188\/21.CJON.431-438","article-title":"Mobile Health Interventions: Examining Medication Adherence Outcomes Among Patients with Cancer","volume":"25","author":"Cazeau","year":"2021","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e10875","DOI":"10.2196\/10875","article-title":"Electronic Systems for Patients to Report and Manage Side Effects of Cancer Treatment: Systematic Review","volume":"21","author":"Warrington","year":"2019","journal-title":"J. Med. Internet Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2013.53.5948","article-title":"What Is the Value of the Routine Use of Patient-Reported Outcome Measures Toward Improvement of Patient Outcomes, Processes of Care, and Health Service Outcomes in Cancer Care? A Systematic Review of Controlled Trials","volume":"32","author":"Kotronoulas","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/jamia\/ocw178","article-title":"To act or not to act: Responses to electronic health record prompts by family medicine clinicians","volume":"24","author":"Zazove","year":"2017","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"103547","DOI":"10.1016\/j.eclinm.2025.103547","article-title":"Statewide integration of electronic patient-reported outcome measures into routine oncology care: A mixed-methods implementation study","volume":"89","author":"Mazariego","year":"2025","journal-title":"eClinicalMedicine"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"100088","DOI":"10.1016\/j.esmorw.2024.100088","article-title":"Implementing digital patient-reported outcomes in routine cancer care: Barriers and facilitators","volume":"6","author":"Aanes","year":"2024","journal-title":"ESMO Real World Data Digit. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Bertolazzi, A., Quaglia, V., and Bongelli, R. (2024). Barriers and facilitators to health technology adoption by older adults with chronic diseases: An integrative systematic review. BMC Public Health, 24.","DOI":"10.1186\/s12889-024-18036-5"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"105122","DOI":"10.1016\/j.healthpol.2024.105122","article-title":"Digital health technologies and inequalities: A scoping review of potential impacts and policy recommendations","volume":"146","author":"Badr","year":"2024","journal-title":"Health Policy"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/14737140.2021.1852934","article-title":"CDK4\/6 inhibitors in breast cancer: Differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis","volume":"21","author":"Onesti","year":"2021","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_45","first-page":"100738","article-title":"Capecitabine efficacy after cycline-dependent-kinase 4\/6 inhibitor plus endocrine therapy in metastatic hormone receptor-positive breast cancer","volume":"36","author":"Bender","year":"2023","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Alt\u0131nta\u015f, Y.E., K\u0131n\u0131ko\u011flu, O., I\u015f\u0131k, D., Batu, A., Bayramgil, A., Ni\u011fdelio\u011flu, B., \u00d6zkerim, U., \u00d6ks\u00fcz, S., S\u00fcrmeli, H., and Turan, N. (2025). Single-Center Real World Study of Everolimus and Exemestane in HR+\/HER2\u2212 Metastatic Breast Cancer Following CDK4\/6 Inhibitor Therapy. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32090503"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"E18761429263841","DOI":"10.2174\/0118761429263841230926014118","article-title":"Deregulated MicroRNAs involved in P53 Signaling Pathway in Breast Cancer with Focus on Triple-negative Breast Cancer","volume":"17","author":"Naeimzadeh","year":"2024","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2019.12.005","article-title":"Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis","volume":"318","author":"Zhao","year":"2020","journal-title":"J. Control. Release"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/5\/272\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T04:34:50Z","timestamp":1778301290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/5\/272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["curroncol33050272"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33050272","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]}}}